Department of Neurology, Dr. RML Hospital & PGIMER, New Delhi

Slides:

Advertisements

Similar presentations

The Drug Discovery Process

Advertisements

Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.

The Aging Brain The brain changes with age The frontal cortex & hippocampus are critical to learning, memory, planning and other cognitive activities,

Considering the pre-clinical and clinical evidence for continuous dopaminergic stimulation (CDS) This educational material has been supported by Abbott.

Neurocognitive Disorders

How Alzheimer’s Disease Differs from Frontal Temporal Lobe Dementia (Pick’s Disease) Josepha A. Cheong, MD University of Florida Departments of Psychiatry.

Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,

Valproic Acid to Treat Agitation in Dementia By: Samia B.

Screening for Stroke and Cognitive Impairment Chapter 2: Background.

Tracie Wymer Julie Franks Shirin Malek Inflammatory Diseases.

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part A – AD definition, neuropath? NUCLEAR MEDICINE GRAND.

Risk of Developing Alzheimer’s Disease in Persons with MCI

Jack Twersky, MD Medical Director CLC Durham.  Memory impairment and at least one of the following  Aphasia  Apraxia  Agnosia  Executive function.

ROLE OF PIRACETAM IN POST- CONCUSSION SYNDROME A PROSPECTIVE RANDOMIZED STUDY Deepak Agrawal, K Naveen*, CS Bal*, AK Mahapatra Departments of Neurosurgery*

MRI as a Potential Surrogate Marker in the ADCS MCI Trial

Food and Drug Administration Regulatory Implications of The WHI Study Eric Colman, MD Center for Drug Evaluation and Research Division of Metabolic and.

CC-1 Benefit-Risk Assessment Murat Emre, MD Professor of Neurology Istanbul Faculty of Medicine Department of Neurology Behavioral Neurology and Movement.

Peripheral and Central Nervous System Drugs Advisory Committee Meeting - March 14, Issues Related to the Development of Drugs for the Treatment.

APRIL AYERS JEFF GIBBERMAN MELISSA HSU EL-KAMARYA SS, SHARDELLA MD, ABDEL-HAMID M, ET AL. A RANDOMIZED CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFICACY.

Introduction Anxiety has been associated with lower work effectiveness and reduced or degraded decision making (Weinberg & Gould, 2003). As such inappropriate.

Vertebral Joint Anatomy Joint Medicine.

Long-Term Efficacy Data for Psychiatric Drugs Thomas Laughren, M.D. Director, Division of Psychiatry Products (HFD-130) PDAC Meeting (Oct 25, 2005)

The use of volunteers in Dementia patients Lizzy Goad Psychology Coordinator Department of Clinical Psychology Salisbury District Hospital.

Background. Vascular Cognitive Impairment Vascular Cognitive Impairment (VCI) includes the cognitive and behavioural disorders associated with cerebrovascular.

NON PHARMACOLOGICAL THERAPY OF MENTAL IMAGERY AND RELAXATION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT Poptsi Ε.,1,3, Κounti F.,1,3,Τsolaki, Μ. 1,2 1.

Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.

The role of Nutrition in Geriatric Mental Health Chih-Chiang Chiu, M.D., Ph.D. Department of Psychiatry, Taipei City Psychiatric Center.

Cannarex "Your One Stop Shop For Marijuana Products" Benenits Of Juicing Raw Marijuana

GINKGO BILOBA AND DONEPEZIL: A COMPARISON IN THE TREATMENT OF THE ALZHEIMER DEMENTIA A RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY Marianna Mazza.

Pharmacological management of delirium

Drug induced cognitive impairment

Most Promising Agents in Treatment of Dementias

Chapter 9 PHARMACOKINETICS VARIABILITY

Nicole C. Hank, MHSM Neurovitality Arizona, United States of America

Vikas Dhikav, PhD Clinical Trials Vikas Dhikav, PhD

Quality of Life Assessment

Yoga in Sexual Dysfunctions

Rivastigmine benefit in ADL and BPSD

Seizures in Alzheimer’s disease

Poststroke dementia Vikas Dhikav,

Management of Agitation in Dementia

Most Promising Agents in Treatment of Dementias

Perceived Caregiver Stress in Alzheimer’s disease and Mild Cognitive Impairment Vikas Dhikav, Pinki Mishra, Arjun Kumar Singhal*, Dolly Prajapati**, Kuljeet.

Chronic HCV Infection and CKD

Cognitive Disorders and Aging

Other drugs used in the treatment of bipolar disorder

Hepatic Encephalopathy protocol - EMB review

Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018

2010/10/14 Presented by R4 謝岳哲 Supervisor VS 薛承君 Moderator VS 黃集仁

DB00103 Category : Enzyme Replacement Agents

Chronic Idiopathic Urticaria

Duloxetine Flavio Guzman, MD.

Li-Yu Tang1, Ta-Fu Chen1,2, Ming-Jang Chiu1,2*

The Modern Management of Asthma: Getting it right Part 2

Sertraline In this section we’ll discuss the most relevant aspects of sertraline.

Clinical Pharmacokinetics

Low risk of sexual dysfunction versus placebo

Bicarbonate in CKD with Acidosis trial

Citalopram and Escitalopram

Venlafaxine and Desvenlafaxine

Collin Belk, Kelly Ferris, Kirsten Carstarphen, Jace Engstler, Dr

Obsessive-Compulsive Disorder: Pharmacotherapy

Nat. Rev. Neurol. doi: /nrneurol

Low risk of sexual dysfunction versus placebo

Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.

The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing

Risk Factors and Therapies for Vascular Dementia:

Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI

ROC curve for the TYM-MCI, ACE-R and MMSE in the separation of patients with aMCI/AD from those with SMC. ACE-R, Addenbrooke’s Cognitive Examinations;

Box plot showing the distribution of the TYM-MCI score for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease;

Presentation transcript:

Department of Neurology, Dr. RML Hospital & PGIMER, New Delhi-110001 Therapeutic Potential of Vinpocetine for Mild Cognitive Impairment & Dementias Vikas Dhikav, Department of Neurology, Dr. RML Hospital & PGIMER, New Delhi-110001 vikasdhikav@hotmail.com

Vinpocetine Vinpocetine is a synthetic ethyl ester of apovincamine, a vinca alkaloid obtained from the leaves of the Lesser Periwinkle (Vinca minor) Cochrane Database Syst Rev. 2003;(1):CD003119.

Pharmacology Cerebral blood-flow enhancing1 Neuroprotective effects Nootropic Increases cerebral metabolism Reheology enhancer2 1Pharmacol Rep. 2011;63(3):618-28, 2Acta Pharm Hung. 1996;66(5):213-24.

Pharmacokinetics Short acting Active metabolite Follows linear pharmacokinetics No accumulation or autoinduction Arzneimittelforschung. 1989;39(12):1599-602.

Potential treatments in dementias Vinpocetine Mifepristone1 Dhikav V, Anand KS. Med Hypotheses. 2007;68(5):1088-92.

Dose Most clinical studies used vinpocetine 10 mg 3 times daily, orally. http://www.drugs.com/npp/vinpocetine.html (Accessed online March 10th 2015)

What is MCI (1) Memory problems (2) Objective memory disorder (3) Absence of other cognitive disorders or repercussions on daily life (4) Normal general cognitive function and (5) Absence of dementia. MCI Working Group. J Neurol Neurosurg Psychiatry. 2006; 77(6): 714–718.

Dementia Memory impairment & at least one of the following: Aphasia Apraxia Agnosia, Disturbances in executive functioning Am J Geriatr Psychiatry. 2011; 19(3): 205–210.

Efficacy in Dementia The three 583 people with dementia placebo control. Benefit vinpocetine 30mg/day and 60 mg/day compared with placebo, Number of patients treated for 6 months or more was small. Cochrane Database Syst Rev. 2003;(1):CD003119.

Safety Clinical trials done so far, suggest good safety of vipocetine. Cochrane Database Syst Rev. 2003;(1):CD003119.

Mild Cognitive Impairment Improvements in memory, attention demonstrated in MCI. Ann Med Health Sci Res. 2014; 4(4): 654–661; Szatmári S, Whitehouse P, Chochrane 2009

Efficacy in dementias “Basic science is interesting, the evidence for beneficial effect of vinpocetine on patients with dementia is inconclusive” Cochrane Database Syst Rev. 2003;(1):CD003119.

Approval status Not currently approved by FDA. Off-label status in India in US. Sold as dietary supplement. Approved in India by DCGI. Asian J Pharm Clin Res 2012; 5 (3), 25-29

Current recommendations Vinpocetine treatment can be recommended for patients with mild cognitive impairment. May improve quality of life in patients with chronic vascular cognitive impairment. Ideggyogy Sz. 2012;65(3-4):115-20.

Thank you